During bone metastasis of prostate cancer, osteoblasts and BMECs stimulated by prostate-derived parathyroid hormone-related protein increase the secretion of CCL2 that could enhance osteoclastic activity and prostate cancer growth in bone [78,153]. This evidence concerns the gene CCL2 and prostate carcinoma.